Kiniksa Pharmaceuticals L... (KNSA)
20.72
1.41 (7.30%)
At close: Apr 14, 2025, 3:59 PM
20.23
-2.36%
After-hours: Apr 14, 2025, 07:54 PM EDT
7.30% (1D)
| Bid | 18.17 |
| Market Cap | 1.51B |
| Revenue (ttm) | 423.24M |
| Net Income (ttm) | -43.19M |
| EPS (ttm) | -0.6 |
| PE Ratio (ttm) | -34.53 |
| Forward PE | 28.69 |
| Analyst | Buy |
| Ask | 23 |
| Volume | 474,707 |
| Avg. Volume (20D) | 686,030.4 |
| Open | 19.73 |
| Previous Close | 19.31 |
| Day's Range | 19.42 - 20.92 |
| 52-Week Range | 16.56 - 28.15 |
| Beta | 0.31 |
About KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclo...
Industry Biotechnology
Sector Healthcare
IPO Date May 25, 2018
Employees 315
Stock Exchange NASDAQ
Ticker Symbol KNSA
Website https://www.kiniksa.com
Analyst Forecast
According to 6 analyst ratings, the average rating for KNSA stock is "Buy." The 12-month stock price forecast is $37.5, which is an increase of 80.98% from the latest price.
Stock ForecastsNext Earnings Release
Kiniksa Pharmaceuticals Ltd. is scheduled to release its earnings on Apr 25, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-15.66%
Kiniksa Pharmaceuticals shares are trading lower a...
Unlock content with
Pro Subscription
8 months ago
+22.91%
Kiniksa Pharmaceuticals shares are trading higher after the company reported better-than-expected Q2 sales results and raised its FY24 net product revenue guidance.
1 month ago · seekingalpha.com
Big Pipeline Updates From Kiniksa PharmaceuticalsBig Pipeline Updates From Kiniksa Pharmaceuticals
